Companies › Cellcolabs Clinical
1 active drug program in 2 registered trials: 2 Phase 1; Cardiovascular, Other; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| StromaForte Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs) | – | Phase 1 | Musculoskeletal Injury; Cardiovascular Diseases | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06074783 | StromaForte | Phase 1 | Musculoskeletal Injury | Other | Oct 2027 |
| NCT06087848 | StromaForte | Phase 1 | Cardiovascular Diseases | Cardiovascular | Oct 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.